Seema Calip
Psychiatry · Beverly Hills, CANPI 1699069203
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Johnson & Johnson at 25.4% of the total. Reporting peaked in 2019 at $1,853 and has fallen 95.3% since, to $87 in 2025.
Across 146 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$773
- AbbVie$701
- Sunovion Pharmaceuticals Inc.$263
- Takeda Pharmaceuticals U.S.A., Inc.$253
- Lundbeck LLC$235
- Vanda Pharmaceuticals Inc.$208
- plus $606 from 10 others
Across 4 payments — averaging $2768.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$11K
What the payments were for
- Food & beverage$3,039100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 38 | $773 |
| AbbVie(2 entities) | 27 | $701 |
| Sunovion Pharmaceuticals Inc. | 18 | $263 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $253 |
| Lundbeck LLC | 11 | $235 |
| Vanda Pharmaceuticals Inc. | 7 | $208 |
| Otsuka America Pharmaceutical, Inc. | 10 | $202 |
| Shire North American Group Inc | 6 | $87 |
| Teva Pharmaceuticals USA, Inc. | 3 | $70 |
| Ironshore Pharmaceuticals Inc. | 3 | $56 |
| Adlon Therapeutics L.p. | 3 | $49 |
| Neuronetics, Inc. | 2 | $41 |
| Merck | 2 | $38 |
| Arbor Pharmaceuticals, Inc. | 1 | $24 |
| Neos Therapeutics, LP | 1 | $20 |
| Bausch Health US, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,039 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 23 | $1,090 |
| Bupropion XlBupropion Hcl | 16 | $280 |
| Duloxetine Hcl | 12 | $151 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Beverly Hills
- Phillip BowmanBeverly Hills$773K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.